CYTO365 is a startup company from Sweden that is already ten years old. The company holds a ISO13485 medical manufacturing certificate. The company has global ambitions and it’s component RondelO™ has the potential to become a new standard for infusion treatment where drugs are to be given in sequence, such as for Chemotherapy but also in other areas.

It is an aim that RondelO™ will become the new standard component within infusion therapy for drugs that should be given in sequence, such as cytostatic drugs. The development phase has come to an end and CYTO365 have started to deliver components to customers. Join us to change the way infusion therapy is delivered.

THE PROBLEM

Drug incompatibilities are frequent, accounting for 20% of all medication errors and up to 89% of administration errors (A). 90% of those treated at hospital get some sort of infusion treatment (B) which is an effective treatment where drugs are entering the patients bloodstream. 74% of the drugs given within infusion therapy should not be mixed (C). 26% of the drugs are potentially life threatening in case they are mixed (D). And a study we have found shows that 46 % of nurses have witnessed drug incompatibility 3-10 times within a month (E), clearly demonstrating the problem with drug incompatibility and the need for flushing fluid in between drugs.  

However, this effective method is vulnerable to adverse event for medical error. Often many drugs are to be given to a patient, but rarely at the same time, rather they should be given in serial with flushing fluid in-between that separates the drugs from reacting with each other that causes drug incompatibility. The main problem addressed is accidental mixing of drugs within infusion therapy causing drug incompatibility.

Furthermore there are 7.3 million nurses in Europe are exposed to hazardous drugs (F) and with RondelO™ it is possible to reduce the exposure. Connect to the inlets of RondelO™, and leave connected to reduce risk of occupational exposure for the nurse.